Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab

BACKGROUND. HER2‐positive gastric cancer (GC) affects 7%–34% of patients with GC. Trastuzumab‐based first‐line treatment has become the standard of care for HER2‐positive advanced gastric cancer (AGC). However, there are no clinically validated biomarkers for resistance to HER2‐targeted therapies. U...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Díaz‐Serrano, Asunción, Angulo, Barbara, Dominguez, Carolina, Pazo‐Cid, Roberto, Salud, Antonieta, Jiménez‐Fonseca, Paula, Leon, Ana, Galan, Maria Carmen, Alsina, Maria, Rivera, Fernando, Plaza, J. Carlos, Paz‐Ares, Luis, Lopez‐Rios, Fernando, Gómez‐Martín, Carlos
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2018
Konular:
Gastrointestinal Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192610/
https://ncbi.nlm.nih.gov/pubmed/29700210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0379
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller